Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:35
06/15/20
06/15
18:35
06/15/20
18:35
LMB

Limbach Holding

$3.34 /

+0.27 (+8.79%)

, LMPX

LMP Automotive

$11.47 /

+1.965 (+20.68%)

, WW

WW

$25.25 /

+0.47 (+1.90%)

, MBIO

Mustang Bio

$3.22 /

-0.025 (-0.77%)

, AYI

Acuity Brands

$97.70 /

+0.08 (+0.08%)

, VICI

VICI Properties

$22.85 /

+0.55 (+2.47%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
WW WW
$25.25 /

+0.47 (+1.90%)

VICI VICI Properties
$22.85 /

+0.55 (+2.47%)

MBIO Mustang Bio
$3.22 /

-0.025 (-0.77%)

LMPX LMP Automotive
$11.47 /

+1.965 (+20.68%)

LMB Limbach Holding
$3.34 /

+0.27 (+8.79%)

AYI Acuity Brands
$97.70 /

+0.08 (+0.08%)

LMB Limbach Holding
$3.34 /

+0.27 (+8.79%)

01/24/20 DA Davidson
Limbach Holding downgraded to Neutral from Buy at DA Davidson
11/18/19 DA Davidson
Limbach Holding price target lowered to $5 from $9 at DA Davidson
08/19/19 DA Davidson
Limbach Holding price target lowered to $9 from $12 at DA Davidson
LMPX LMP Automotive
$11.47 /

+1.965 (+20.68%)

02/21/20 ThinkEquity
LMP Automotive initiated with a Buy at ThinkEquity
WW WW
$25.25 /

+0.47 (+1.90%)

06/12/20 Guggenheim
WW initiated with a Buy at Guggenheim
05/13/20
Fly Intel: Top five analyst initiations
05/12/20 Jefferies
WW initiated with a Buy at Jefferies
05/12/20 Jefferies
WW initiated with a Buy at Jefferies
MBIO Mustang Bio
$3.22 /

-0.025 (-0.77%)

02/18/20 H.C. Wainwright
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright
01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
AYI Acuity Brands
$97.70 /

+0.08 (+0.08%)

06/15/20 Goldman Sachs
Acuity Brands downgraded to Sell from Neutral at Goldman Sachs
06/09/20 JMP Securities
Acuity Brands downgraded to Market Perform from Outperform at JMP Securities
06/08/20 Oppenheimer
Acuity Brands upgraded to Outperform at Oppenheimer
06/08/20 Oppenheimer
Acuity Brands upgraded to Outperform from Perform at Oppenheimer
VICI VICI Properties
$22.85 /

+0.55 (+2.47%)

06/12/20 SunTrust
SunTrust raises price target on select Gaming names amid positive room-rate data
05/04/20 Deutsche Bank
VICI Properties price target lowered to $24 from $31 at Deutsche Bank
05/04/20 Deutsche Bank
VICI Properties price target lowered to $24 from $31 at Deutsche Bank
04/28/20 Ladenburg
VICI Properties price target lowered to $21 from $28.50 at Ladenburg
WW WW
$25.25 /

+0.47 (+1.90%)

VICI VICI Properties
$22.85 /

+0.55 (+2.47%)

LMB Limbach Holding
$3.34 /

+0.27 (+8.79%)

AYI Acuity Brands
$97.70 /

+0.08 (+0.08%)

  • 17
    Jun
VICI VICI Properties
$22.85 /

+0.55 (+2.47%)

WW WW
$25.25 /

+0.47 (+1.90%)

MBIO Mustang Bio
$3.22 /

-0.025 (-0.77%)

AYI Acuity Brands
$97.70 /

+0.08 (+0.08%)

WW WW
$25.25 /

+0.47 (+1.90%)

Hot Stocks
Mustang Bio CEO Litchman purchases $500K in company shares » 16:39
06/15/20
06/15
16:39
06/15/20
16:39
MBIO

Mustang Bio

$3.22 /

-0.025 (-0.77%)

Mustang Bio CEO Manuel…

Mustang Bio CEO Manuel Litchman purchased 153,846 shares of company stock at an average price of $3.25 on June 11. The total transaction amount was $500,000.

ShowHide Related Items >><<
MBIO Mustang Bio
$3.22 /

-0.025 (-0.77%)

MBIO Mustang Bio
$3.22 /

-0.025 (-0.77%)

02/18/20 H.C. Wainwright
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright
01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
MBIO Mustang Bio
$3.22 /

-0.025 (-0.77%)

Syndicate
Mustang Bio 10.79M share Spot Secondary priced at $3.25 » 09:12
06/11/20
06/11
09:12
06/11/20
09:12
MBIO

Mustang Bio

$3.74 /

-0.5 (-11.79%)

Cantor Fitzgerald acted…

Cantor Fitzgerald acted as sole book running manager for the offering.

ShowHide Related Items >><<
MBIO Mustang Bio
$3.74 /

-0.5 (-11.79%)

MBIO Mustang Bio
$3.74 /

-0.5 (-11.79%)

02/18/20 H.C. Wainwright
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright
01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
  • 11
    Jun
MBIO Mustang Bio
$3.74 /

-0.5 (-11.79%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
06/11/20
06/11
08:56
06/11/20
08:56
SRNE

Sorrento Therapeutics

$4.57 /

-0.2 (-4.19%)

, GRUB

GrubHub

$59.85 /

+1.93 (+3.33%)

, HEXO

Hexo

$1.02 /

-0.07 (-6.42%)

, TLRD

Tailored Brands

$1.24 /

-0.11 (-8.15%)

, PLCE

Children's Place

$47.03 /

-0.68 (-1.43%)

, OXM

Oxford Industries

$51.71 /

-3.32 (-6.03%)

, TSLA

Tesla

$1,021.00 /

+79.46 (+8.44%)

, MBIO

Mustang Bio

$3.74 /

-0.5 (-11.79%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
TSLA Tesla
$1,021.00 /

+79.46 (+8.44%)

TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

SRNE Sorrento Therapeutics
$4.57 /

-0.2 (-4.19%)

PLCE Children's Place
$47.03 /

-0.68 (-1.43%)

OXM Oxford Industries
$51.71 /

-3.32 (-6.03%)

MBIO Mustang Bio
$3.74 /

-0.5 (-11.79%)

HEXO Hexo
$1.02 /

-0.07 (-6.42%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

SRNE Sorrento Therapeutics
$4.57 /

-0.2 (-4.19%)

05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
10/07/19 JMP Securities
Sorrento Therapeutics initiated with an Outperform at JMP Securities
07/23/19 H.C. Wainwright
Sorrento Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

06/11/20 Craig-Hallum
GrubHub price target raised to $65 from $45 at Craig-Hallum
06/11/20 Wedbush
GrubHub price target raised to $75 from $38 at Wedbush
06/11/20 Deutsche Bank
GrubHub deal valued at $65 per share, says Deutsche Bank
06/11/20 Deutsche Bank
GrubHub sale 'clear negative' for Uber, says Deutsche Bank
HEXO Hexo
$1.02 /

-0.07 (-6.42%)

04/15/20 Alliance Global Partners
Hexo price target lowered to C$1.50 from C$2.50 at Alliance Global Partners
03/31/20
Fly Intel: Top five analyst downgrades
03/31/20 BofA
Hexo resumed with an Underperform at BofA
03/31/20 Desjardins
Hexo downgraded to Hold from Buy at Desjardins
TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

03/19/20 Deutsche Bank
Tailored Brands price target lowered to $1 from $4 at Deutsche Bank
06/13/19 B. Riley FBR
Tailored Brands price target lowered to $7 from $10 at B. Riley FBR
PLCE Children's Place
$47.03 /

-0.68 (-1.43%)

06/09/20 Wedbush
Children's Place price target raised to $45 from $34 at Wedbush
05/19/20 Deutsche Bank
Children's Place price target raised to $44 from $39 at Deutsche Bank
05/18/20 Wedbush
Children's Place price target raised to $34 from $25 at Wedbush
04/20/20 Deutsche Bank
Children's Place price target raised to $39 from $30 at Deutsche Bank
OXM Oxford Industries
$51.71 /

-3.32 (-6.03%)

06/08/20 Needham
Oxford Industries price target raised to $62 from $50 at Needham
03/27/20 KeyBanc
Oxford Industries price target lowered to $54 from $86 at KeyBanc
01/29/20 Needham
Oxford Industries upgraded to Buy from Hold at Needham
01/29/20 Needham
Oxford Industries upgraded to Buy from Hold at Needham
TSLA Tesla
$1,021.00 /

+79.46 (+8.44%)

06/10/20 Wedbush
Tesla price target raised to $1,000 from $800 at Wedbush
06/10/20 Wedbush
Tesla price target raised to $1,000 from $800 at Wedbush
06/01/20 Morgan Stanley
SpaceX success has bearing on market's perception of Tesla, says Morgan Stanley
05/29/20
Fly Intel: Top five analyst initiations
MBIO Mustang Bio
$3.74 /

-0.5 (-11.79%)

02/18/20 H.C. Wainwright
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright
01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
TSLA Tesla
$1,021.00 /

+79.46 (+8.44%)

TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

PLCE Children's Place
$47.03 /

-0.68 (-1.43%)

OXM Oxford Industries
$51.71 /

-3.32 (-6.03%)

HEXO Hexo
$1.02 /

-0.07 (-6.42%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

  • 11
    Jun
TSLA Tesla
$1,021.00 /

+79.46 (+8.44%)

TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

SRNE Sorrento Therapeutics
$4.57 /

-0.2 (-4.19%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

TSLA Tesla
$1,021.00 /

+79.46 (+8.44%)

TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

SRNE Sorrento Therapeutics
$4.57 /

-0.2 (-4.19%)

PLCE Children's Place
$47.03 /

-0.68 (-1.43%)

HEXO Hexo
$1.02 /

-0.07 (-6.42%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

TSLA Tesla
$1,021.00 /

+79.46 (+8.44%)

TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

SRNE Sorrento Therapeutics
$4.57 /

-0.2 (-4.19%)

PLCE Children's Place
$47.03 /

-0.68 (-1.43%)

OXM Oxford Industries
$51.71 /

-3.32 (-6.03%)

HEXO Hexo
$1.02 /

-0.07 (-6.42%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

TSLA Tesla
$1,021.00 /

+79.46 (+8.44%)

On The Fly
Fly Intel: After-Hours Movers » 19:02
06/10/20
06/10
19:02
06/10/20
19:02
TLRD

Tailored Brands

$1.24 /

-0.11 (-8.15%)

, JACK

Jack in the Box

$71.09 /

-0.38 (-0.53%)

, GRUB

GrubHub

$59.85 /

+1.93 (+3.33%)

, PSNL

Personalis

$13.05 /

-0.09 (-0.68%)

, SRT

StarTek

$4.92 /

-0.16 (-3.15%)

, OXM

Oxford Industries

$51.71 /

-3.32 (-6.03%)

, MBIO

Mustang Bio

$3.74 /

-0.5 (-11.79%)

, CTLT

Catalent

$74.61 /

-0.29 (-0.39%)

, CIM

Chimera

$10.61 /

-0.54 (-4.84%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

SRT StarTek
$4.92 /

-0.16 (-3.15%)

PSNL Personalis
$13.05 /

-0.09 (-0.68%)

OXM Oxford Industries
$51.71 /

-3.32 (-6.03%)

MBIO Mustang Bio
$3.74 /

-0.5 (-11.79%)

JACK Jack in the Box
$71.09 /

-0.38 (-0.53%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

CTLT Catalent
$74.61 /

-0.29 (-0.39%)

CIM Chimera
$10.61 /

-0.54 (-4.84%)

TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

03/19/20 Deutsche Bank
Tailored Brands price target lowered to $1 from $4 at Deutsche Bank
06/13/19 B. Riley FBR
Tailored Brands price target lowered to $7 from $10 at B. Riley FBR
JACK Jack in the Box
$71.09 /

-0.38 (-0.53%)

05/27/20
Fly Intel: Top five analyst upgrades
05/26/20 Goldman Sachs
Jack in the Box upgraded to Neutral from Sell at Goldman Sachs
05/26/20 Goldman Sachs
Jack in the Box upgraded to Neutral from Sell at Goldman Sachs
05/15/20 SunTrust
Jack in the Box price target raised to $86 from $79 at SunTrust
GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

06/10/20 BTIG
GrubHub initiated with a Neutral at BTIG
06/10/20 Needham
Logic of GrubHub takeover by Just Eat 'looks questionable,' says Needham
06/09/20 Jefferies
GrubHub price target raised to $62 from $50 at Jefferies
06/08/20 Jefferies
Uber can likely bid higher than EU rivals for GrubHub, says Jefferies
PSNL Personalis
$13.05 /

-0.09 (-0.68%)

11/14/19 Oppenheimer
Personalis price target lowered to $26 from $29 at Oppenheimer
09/26/19 BofA
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
09/26/19 BofA
Personalis upgraded to Buy from Neutral at BofA/Merrill
07/15/19 Cowen
Personalis initiated with an Outperform at Cowen
SRT StarTek
$4.92 /

-0.16 (-3.15%)

04/08/20 B. Riley FBR
StarTek price target lowered to $6 from $10.50 at B. Riley FBR
03/13/20 Lake Street
StarTek valuation compelling after strong Q4, says Lake Street
01/09/20
Fly Intel: Top five analyst initiations
01/09/20 B. Riley FBR
B. Riley FBR starts StarTek with Buy rating, $10.50 price target
OXM Oxford Industries
$51.71 /

-3.32 (-6.03%)

06/08/20 Needham
Oxford Industries price target raised to $62 from $50 at Needham
03/27/20 KeyBanc
Oxford Industries price target lowered to $54 from $86 at KeyBanc
01/29/20 Needham
Oxford Industries upgraded to Buy from Hold at Needham
01/29/20 Needham
Oxford Industries upgraded to Buy from Hold at Needham
MBIO Mustang Bio
$3.74 /

-0.5 (-11.79%)

02/18/20 H.C. Wainwright
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright
01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
CTLT Catalent
$74.61 /

-0.29 (-0.39%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
CIM Chimera
$10.61 /

-0.54 (-4.84%)

05/18/20 RBC Capital
Chimera price target lowered to $11 from $23 at RBC Capital
10/02/19 RBC Capital
RBC Capital initiates select mortgage REITs with 'constructive' outlook
10/02/19 RBC Capital
Chimera initiated with an Outperform at RBC Capital
10/02/19 RBC Capital
Chimera initiated with an Outperform at RBC Capital
TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

SRT StarTek
$4.92 /

-0.16 (-3.15%)

PSNL Personalis
$13.05 /

-0.09 (-0.68%)

OXM Oxford Industries
$51.71 /

-3.32 (-6.03%)

JACK Jack in the Box
$71.09 /

-0.38 (-0.53%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

CTLT Catalent
$74.61 /

-0.29 (-0.39%)

CIM Chimera
$10.61 /

-0.54 (-4.84%)

  • 11
    Jun
  • 11
    Jun
TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

CTLT Catalent
$74.61 /

-0.29 (-0.39%)

TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

JACK Jack in the Box
$71.09 /

-0.38 (-0.53%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

CIM Chimera
$10.61 /

-0.54 (-4.84%)

TLRD Tailored Brands
$1.24 /

-0.11 (-8.15%)

OXM Oxford Industries
$51.71 /

-3.32 (-6.03%)

GRUB GrubHub
$59.85 /

+1.93 (+3.33%)

CIM Chimera
$10.61 /

-0.54 (-4.84%)

Syndicate
Mustang Bio files to sell common stock, no amount given » 16:01
06/10/20
06/10
16:01
06/10/20
16:01
MBIO

Mustang Bio

$4.63 /

+0.385 (+9.08%)

Cantor Fitzgerald &…

Cantor Fitzgerald & Co. is acting as the sole book running manager for the offering.

ShowHide Related Items >><<
MBIO Mustang Bio
$4.63 /

+0.385 (+9.08%)

MBIO Mustang Bio
$4.63 /

+0.385 (+9.08%)

02/18/20 H.C. Wainwright
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright
01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
Hot Stocks
Mustang Bio announces presentations at ASGCT meeting » 08:39
05/12/20
05/12
08:39
05/12/20
08:39
MBIO

Mustang Bio

$3.18 /

+0.39 (+13.98%)

Mustang Bio announced two…

Mustang Bio announced two poster presentations at the virtual 23rd Annual Meeting of the American Society of Gene & Cell Therapy, being held May 12-15, 2020. Details on the poster presentations are as follows: Title: CS1 Targeted CAR-T Cells for the Treatment of Multiple Myeloma Shows Antitumor Activity Sparing Normal T-Cells Despite the Common Expression of CS1: This poster describes researchers' investigation into the impact of MB-104 on CS1 positive and negative cells in vitro, as well as T cells due to shared CS1 antigen expansion. The researchers demonstrated MB-104 does not confer biologically significant fratricide and can be successfully manufactured as evident by viability, growth kinetics and fold expansion, despite the shared antigen expression between tumor cells and T cells. CS1 positive T cells are present in culture during the expansion of MB-104, suggesting absence of fratricide. Finally, MB-104 can induce potent anti-tumor cell lysis and proliferates in response to tumor cells but not primary T cells expressing CS1. Taken together, their results demonstrate MB-104 is a novel CS1-targeting CAR T that shows potent anti-tumor cell lysis but spares normal T cells, despite the shared CS1 antigen expression. Title: Development of an Immunohistochemistry Assay for the Detection of CS-1 Expression in Multiple Myeloma Patients: This poster details a study in which researchers evaluated commercially available CS1 antibodies for IHC and identified the best clone with high specificity for CS1 to improve screening subjects for CS1 positive tumor expression prior to treatment and correlate efficacy with antigen expression. The researchers, for the first time, developed and optimized a robust immunohistochemistry assay for the assessment of CS1 expression in bone marrow core biopsy samples and plasmacytoma solid tumor samples from multiple myeloma patients, which can be used for enrollment into Mustang's CS1 CAR T clinical trials.

ShowHide Related Items >><<
MBIO Mustang Bio
$3.18 /

+0.39 (+13.98%)

MBIO Mustang Bio
$3.18 /

+0.39 (+13.98%)

02/18/20 H.C. Wainwright
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright
01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
Hot Stocks
Mustang Bio receives ATMP classification for MB-107 lentiviral gene therapy » 08:09
04/20/20
04/20
08:09
04/20/20
08:09
MBIO

Mustang Bio

$2.97 /

+0.18 (+6.45%)

Mustang Bio announced…

Mustang Bio announced that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification to MB-107, Mustang's lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease. The U.S. Food and Drug Administration previously granted Regenerative Medicine Advanced Therapy designation to MB-107 for the treatment of XSCID in August 2019. EMA grants ATMP classifications to new therapeutics that are based on genes or cells and intended as long-term or permanent therapeutic solutions to acute or chronic human diseases at a genetic, cellular or tissue level. The ATMP program provides specific regulatory guidelines for preclinical development, manufacturing and product quality testing of ATMPs and offers incentives, including fee reductions for regulatory advice, recommendations and evaluation and certification of quality and non-clinical data. MB-107 is currently being assessed in two Phase 1/2 clinical trials for XSCID: the first in newly diagnosed infants under the age of two at St. Jude Children's Research Hospital, UCSF Benioff Children's Hospital in San Francisco and Seattle Children's Hospital and the second in patients over the age of two who have received prior hematopoietic stem cell transplantation at the National Institutes of Health. Under a licensing partnership with St. Jude, Mustang intends to develop the lentiviral gene therapy for commercial use as MB-107.

ShowHide Related Items >><<
MBIO Mustang Bio
$2.97 /

+0.18 (+6.45%)

02/18/20 H.C. Wainwright
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright
01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
Over a quarter ago
Recommendations
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright » 11:25
02/18/20
02/18
11:25
02/18/20
11:25
MBIO

Mustang Bio

$3.74 /

-0.015 (-0.40%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis notes that Mustang Bio announced that its drug candidate MB-106 scored the first complete response in the first patient treated in the ongoing MB-106 Phase 1/2 trial. The analyst also points out that "this encouraging first clinical win" was observed following 28 days, after one single low dose of CARs and with no toxicity, such as cytokine release syndrome and neurotoxicity. Pantginis expects to see follow-up data of the trial at upcoming meetings, likely at ASH, by year-end 2020. The analyst has a Buy rating and $7 price target on the shares.

ShowHide Related Items >><<
MBIO Mustang Bio
$3.74 /

-0.015 (-0.40%)

01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
06/21/19 Cantor Fitzgerald
Cantor starts Mustang Bio with Overweight rating, $7 price target
Hot Stocks
Mustang Bio announces first subject reated in Phase 1/2 trial of MB-106 » 08:15
02/18/20
02/18
08:15
02/18/20
08:15
MBIO

Mustang Bio

$3.76 /

-0.015 (-0.40%)

Mustang Bio announced…

Mustang Bio announced that the first subject treated with the optimized MB-106 manufacturing process, developed in collaboration between Mustang and Fred Hutchinson Cancer Research Center has achieved a complete response at the lowest starting dose in an ongoing Phase 1/2 clinical trial. The trial is evaluating the safety and efficacy of MB-106 in subjects with relapsed or refractory B-cell non-Hodgkin lymphomas. The Phase 1/2, open-label, dose-escalation trial is evaluating the maximum tolerated dose of MB-106. Secondary endpoints include safety and toxicity, preliminary antitumor activity as measured by overall response rate and complete remission rate, progression-free survival, and overall survival. Fred Hutch intends to enroll approximately 30 subjects on the trial, which is being led by principal investigator Mazyar Shadman, M.D., M.P.H., Assistant Member of Fred Hutch's Clinical Research Division.

ShowHide Related Items >><<
MBIO Mustang Bio
$3.76 /

-0.015 (-0.40%)

01/09/20 Cantor Fitzgerald
Mustang Bio named top pick for 2020 at Cantor Fitzgerald
11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
06/21/19 Cantor Fitzgerald
Cantor starts Mustang Bio with Overweight rating, $7 price target

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.